1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW

3. MARKET DYNAMICS
3.1. MARKET DEFINITION
3.2. KEY DRIVERS
3.2.1. INCREASING ROAD ACCIDENTS AND SURGICAL PROCEDURES
3.2.2. ESCALATING PALLIATIVE CARE FOR PATIENTS SUFFERING INTENSELY
3.2.3. USAGE OF ABUSE DETERRENT FORMULATIONS TO RESTRICT THE OPIOID ABUSE
3.2.4. GROWING OCCURRENCE OF CHRONIC PAIN
3.3. KEY RESTRAINTS
3.3.1. MISUSE OF OPIOIDS
3.3.2. STRINGENT REGULATORY FRAMEWORK

4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. REGULATORY FRAMEWORK
4.6. TECHNOLOGICAL ADVANCEMENT

5. MARKET BY PRODUCT
5.1. BUPRENORPHINE
5.2. FENTANYL
5.3. HYDROCODONE
5.4. MORPHINE
5.5. OXYCODONE
5.6. TRAMADOL
5.7. OTHER PRODUCTS

6. MARKET BY APPLICATION
6.1. PAIN RELIEF
6.1.1. CANCER PAIN
6.1.2. POSTOPERATIVE PAIN MANAGEMENT
6.1.3. LOW BACK PAIN
6.1.4. ORTHOPEDIC
6.1.5. FIBROMYALGIA
6.1.6. NEUROPATHIC
6.2. ANESTHESIA
6.3. COUGH SUPPRESSION
6.4. DIARRHEA SUPPRESSION
6.5. DEADDICTION

7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC
7.1.1. CHINA
7.1.2. JAPAN
7.1.3. INDIA
7.1.4. SOUTH KOREA
7.1.5. INDONESIA
7.1.6. THAILAND
7.1.7. VIETNAM
7.1.8. AUSTRALIA & NEW ZEALAND
7.1.9. REST OF ASIA PACIFIC

8. COMPANY PROFILES
8.1. ACURA PHARMACEUTICALS INC
8.2. ALLERGAN PLC
8.3. BIODELIVERY SCIENCES INTERNATIONAL INC
8.4. CIPHER PHARMACEUTICALS INC
8.5. COLLEGIUM PHARMACEUTICAL INC
8.6. DAIICHI SANKYO INC
8.7. EGALET CORP
8.8. HIKMA PHARMACEUTICALS PLC
8.9. INDIVIOR INC
8.10. JANSSEN PHARMACEUTICALS INC
8.11. JOHNSON & JOHNSON
8.12. LANNETT CO. INC
8.13. LUPIN LTD
8.14. MYLAN NV
8.15. PFIZER INC
8.16. PURDUE PHARMA LP
8.17. SANOFI-AVENTIS S.A
8.18. SUN PHARMACEUTICAL INDUSTRIES LIMITED (SUN PHARMA)
8.19. TEVA PHARMACEUTICAL INDUSTRIES LTD